Liposome delivery systems for the treatment of Alzheimer’s disease

Ross, Callum and Taylor, Mark Neville and Fullwood, Nigel James and Allsop, David (2018) Liposome delivery systems for the treatment of Alzheimer’s disease. International Journal of Nanomedicine, 2018 (13). pp. 8507-8522. ISSN 1178-2013

[img]
Preview
PDF (International Journal of Nanomedicine (2018))
International_Journal_of_Nanomedicine_2018_.pdf - Published Version
Available under License Creative Commons Attribution-NonCommercial-NoDerivs.

Download (3MB)

Abstract

Alzheimer’s disease (AD) will affect around 115 million people worldwide by the year 2050. It is associated with the accumulation of misfolded and aggregated proteins (β-amyloid and tau) in the senile plaques and neurofibrillary tangles found in the brain. Currently available drugs for AD only temporarily alleviate symptoms and do not slow the inevitable progression of this disease. New drugs are required that act on key pathologies in order to arrest or reverse cognitive decline. However, there has been a spectacular failure rate in clinical trials of conventional small molecule drugs or biological agents. Targeted nanoliposomes represent a viable and promising drug delivery system for AD that have not yet reached clinical trials. They are biocompatible, highly flexible, and have the potential to carry many different types of therapeutic molecules across the blood–brain barrier (BBB) and into brain cells. They can be tailored to extend blood circulation time and can be directed against individual or multiple pathological targets. Modifications so far have included the use of brain-penetrating peptides, together with Aβ-targeting ligands, such as phosphatidic acid, curcumin, and a retro-inverted peptide that inhibits Aβ aggregation. Combining several modifications together into multifunctional liposomes is currently a research area of great interest. This review focuses on recent liposomal approaches to AD therapy, including mechanisms involved in facilitating their passage across the BBB, and the evaluation of new therapeutic agents for blocking Aβ and/or tau aggregation.

Item Type:
Journal Article
Journal or Publication Title:
International Journal of Nanomedicine
Uncontrolled Keywords:
/dk/atira/pure/subjectarea/asjc/1300/1304
Subjects:
ID Code:
129678
Deposited By:
Deposited On:
12 Dec 2018 15:18
Refereed?:
Yes
Published?:
Published
Last Modified:
26 Sep 2020 05:43